CLOBAZAM

Course overview

CLOBAZAM WAS SYNTHESIZED IN THE 1960S WITH A PRIMARY GOAL OF PROVIDING GREATER EFFICACY WITH FEWER BENZODIAZEPINE-RELATED SIDE EFFECTS. FDA INDICATIONS INCLUDE ADJUNCTIVE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX–GASTAUT SYNDROME IN PATIENTS TWO YEARS OR OLDER, NONFDA-APPROVED INDICATIONS INCLUDE ADJUNCTIVE THERAPY FOR SEIZURES SEEN WITH DRAVET SYNDROME, ADJUNCTIVE THERAPY FOR REFRACTORY STATUS EPILEPTICUS, ADJUNCTIVE THERAPY OF REFRACTORY FOCAL EPILEPSY, CATAMENIAL EPILEPSY, AND ANXIETY. THIS ACTIVITY REVIEWS INDICATIONS, MECHANISM OF ACTION, ADMINISTRATION, CONTRAINDICATIONS, MONITORING, AND TOXICITY ASSOCIATED WITH CLOBAZAM, AND THE ROLE OF THE INTERPROFESSIONAL TEAM IN CARING FOR PATIENTS WITH CONDITIONS THAT INDICATE THERAPY WITH CLOBAZAM.